Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives

Phillips, Oludotun A.; D’silva, Roselyn Jennifer; Bahta, Teklu O.; Sharaf, Leyla H.; Udo, Edet E.; Benov, Ludmil; Walters, D. Eric

doi:10.1016/j.ejmech.2015.10.025

Cited by 22 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[55] In 2015, Fresno et al used molecular modelling techniques to search for peroxisome proliferator-activatedr eceptor (PPAR) agonists, whichl ed to identification of oxazolidinone-based molecules as potent PPAR agonists. [57] Similarly,o ther reports exploring the antimicrobial potential of oxazolidinones were also published after 2013. Furthermore, the authors developed as eries of chiral ligands of PPARs.…”

Section: Pharmacological Profile Of Oxazolidinone Derivativesmentioning

confidence: 99%

The Current Status of O‐Heterocycles: A Synthetic and Medicinal Overview

Singh

Silakari

2018

ChemMedChem

View full text Add to dashboard Cite

O-Heterocycles have been explored in the field of medicinal chemistry for a long time, but their significance has not been duly recognised and they are often shunned in favour of N-heterocycles. The design of bioactive molecules for nearly every pathophysiological condition is primarily focused on novel N-heterocycles. The main reasons for such bias include the ease of synthesis and possible mimicking of physiological molecules by N-heterocycles. But considering only this criterion rarely provides breakthrough molecules for a given disease condition, and instead the risks of toxicity or side effects are increased with such molecules. On the other hand, owing to improved synthetic feasibility, O-heterocycles have established themselves as equally potent lead molecules for a wide range of pathophysiological conditions. In the last decade there have been hundreds of reports validating the fact that equally potent molecules can be designed and developed by using O-heterocycles, and these are also expected to have comparably low toxicity. Even so, researchers tend to remain biased toward the use of N-heterocycles over O-heterocycles. Thus, this review provides a critical analysis of the synthesis and medicinal attributes of O-heterocycles, such as pyrones, oxazolones, furanones, oxetanes, oxazolidinones, and dioxolonones, and others, reported in the last five years, underlining the need for and the advantages guiding researchers toward them.

show abstract

Section: Pharmacological Profile Of Oxazolidinone Derivativesmentioning

confidence: 99%

The Current Status of O‐Heterocycles: A Synthetic and Medicinal Overview

Singh

Silakari

2018

ChemMedChem

View full text Add to dashboard Cite

show abstract

“…With a view to further explore this scaffold, the same group (2015) evaluated a series of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives for MAO-B inhibitory activities ( Figure 58). 202 While most of the compounds These results demonstrated that the introduction of second chlorine atom in 5-phenyl substituent improved potency.…”

Section: Linear and Macrocyclic Carboxamide Derivativesmentioning

confidence: 90%

“…With a view to further explore this scaffold, the same group (2015) evaluated a series of novel 5‐(hydroxamic acid)methyl oxazolidinone derivatives for MAO‐B inhibitory activities (Figure ) . While most of the compounds tested showed selective MAO‐B inhibition, they demonstrated only moderate to weak MAO‐B inhibitory activities with IC 50 values in micromolar to submicromolar range ( 142a ‐ i ).…”

Section: Discovery and Development Of Mao‐b Inhibitors (2015‐2018)mentioning

confidence: 99%

“…Oxazolidinone hydroxamic acid ( 142a ‐ i ) . hMAO, human monoamine oxidase; IC 50 , half maximal inhibitory concentration…”

Section: Discovery and Development Of Mao‐b Inhibitors (2015‐2018)mentioning

confidence: 99%

“…synthesized a library of novel arylalkenylpropargylamines and tested them for inhibitory activities against MAOs(Figure 60). A number of highly potent and F I G U R E 5 8 Oxazolidinone hydroxamic acid (142a-i) 202. hMAO, human monoamine oxidase; IC 50 , half maximal inhibitory concentration TRIPATHI AND AYYANNAN | 1653 selective MAO-BIs were identified.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Monoamine oxidase‐B inhibitors as potential neurotherapeutic agents: An overview and update

Tripathi

Ayyannan

2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Monoamine oxidase (MAO) inhibitors have made significant contributions and remain an indispensable approach of molecular and mechanistic diversity for the discovery of antineurodegenerative drugs. However, their usage has been hampered by nonselective and/or irreversible action which resulted in drawbacks like liver toxicity, cheese effect, and so forth. Hence, the search for selective MAO inhibitors (MAOIs) has become a substantial focus in current drug discovery. This review summarizes our current understanding on MAO‐A/MAO‐B including their structure, catalytic mechanism, and biological functions with emphases on the role of MAO‐B as a potential therapeutic target for the development of medications treating neurodegenerative disorders. It also highlights the recent developments in the discovery of potential MAO‐B inhibitors (MAO‐BIs) belonging to diverse chemical scaffolds, arising from intensive chemical‐mechanistic and computational studies documented during past 3 years (2015‐2018), with emphases on their potency and selectivity. Importantly, readers will gain knowledge of various newly established MAO‐BI scaffolds and their development potentials. The comprehensive information provided herein will hopefully accelerate ideas for designing novel selective MAO‐BIs with superior activity profiles and critical discussions will inflict more caution in the decision‐making process in the MAOIs discovery.

show abstract

The Oxazolidinones

Barbachyn

2017

Topics in Medicinal Chemistry

View full text Add to dashboard Cite

Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives

Cited by 22 publications

References 28 publications

The Current Status of O‐Heterocycles: A Synthetic and Medicinal Overview

The Current Status of O‐Heterocycles: A Synthetic and Medicinal Overview

Monoamine oxidase‐B inhibitors as potential neurotherapeutic agents: An overview and update

The Oxazolidinones

Contact Info

Product

Resources

About